Limbix

About Limbix

Founded in 2016 by Ben Lewis and Jon Sockell, Limbix operates at the intersection of technology and adolescent mental health. Lewis, with a background as an Engineering Manager at Facebook and founder of two other companies, and Sockell, a former Director of Marketing, established the company to address the critical need for accessible mental health treatments for young people. The company initially explored virtual reality for exposure therapy but pivoted in late 2019 to focus on mobile-based digital therapeutics. After raising a total of $31 million over several funding rounds, with notable contributions from investors like GSR Ventures and Sequoia Capital, Limbix was acquired by Big Health in July 2023.

Limbix develops prescription digital therapeutics (PDTs), which are software-based interventions prescribed by healthcare professionals to treat medical conditions. The company's business model targets health systems and payors, aiming to integrate its products into the existing healthcare framework as a new, evidence-based treatment option. This approach allows clinicians to prescribe the digital tools as an adjunct to traditional therapy for adolescents aged 13 to 22.

The company's flagship product is SparkRx, a smartphone application designed to help manage symptoms of adolescent depression. SparkRx is a multi-week, self-guided program based on the principles of Cognitive Behavioral Therapy (CBT), with a specific focus on behavioral activation. It uses features like mood tracking, problem-solving exercises, mindfulness activities, and a supportive chatbot named 'Limbot' to teach users coping skills and the relationship between their mood and actions. Clinical studies have shown that SparkRx can lead to a statistically significant reduction in depression symptoms. The product was launched under an FDA enforcement policy related to the COVID-19 pandemic, which permitted marketing without full FDA clearance to improve access to psychiatric digital health devices.